vTv Therapeutics Inc.

Healthcare · Biotechnology · United States

Last price 25.17 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 312.73M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to dev...